Method of treating brain tumors expressing tenascin

Details Method of treating brain tumors expressing tenascin Method of treating brain tumors expressing tenascin

1995-02-22

1997-04-29

Eisenschenk, Frank C.

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

Attached to antibody or antibody fragment or immunoglobulin;...

5303913, 5303911, 5303888, 5303897, 53038885, 5303891, 4241781, 4241811, A61K 5110, A61K 39395, C07K 1628, C07K 1630

Patent

active

056246595

ABSTRACT:
Methods of treating solid and cystic tumors are disclosed. The method comprises administering to a subject afflicted with a cystic tumor an antibody which binds to tenascin in a therapeutically effective amount. The administering step is carried out by depositing the antibody in the cyst cavity of the cystic tumor. For solid tumors, disclosed is a method involving first, removing a solid tumor from a solid tissue organ of an afflicted subject; then forming an enclosed resection cavity in the organ of the subject at the location from which the solid tumor was removed; and then administering to the subject an antineoplastic agent by depositing the antineoplastic agent in the resection cavity. Particularly preferred for carrying out the foregoing is the monoclonal antibody 81C6 and antibodies which bind to the epitope bound by monoclonal antibody 81C6.

REFERENCES:
Halperin, Int. J. Radia. Oncol. Biol. Phys., 1988, 15:505.
Goldenberg, CA Cancer J Clin., 1994, 44:43.
Papanastassiou et al., Medlars Database, Mar. 1992.
Riva et al., Int. J. Cancer, 51:7, Apr. 1992.
M. Bourdon et al., Cancer Research 43, 2796-2805 (1983).
L. S. Lashford et al., Cancer 61, 857-868 (1988).
R.P. Moseley et al., Br. J. Cancer 62, 637-642 (1990).
R.P. Moseley et al., Int. J. Cancer 52, 38-43 (1992).
V. Papanastassiou et al., J. Neurooncology 12, 268 (1992).
P. Riva et al., Nuclear Medicine Communications 13, 635 (1992).
J. M. Schuster et al., Cancer Research 57, 4164-4169 (1991).
M.R. Zalutsky et al., Cancer Research 49, 5543-5549 (1989).
E.V. Colapinto et al., Cancer Research 50, 1822-1827 (1990).
Riva et al., Int. J. Cancer, 51:7, 1992.
Zalutsky et al., Cancer Res., 50:4105, 1990, Monoclonal . . . Administration .
Zalutsky et al., Cancer Res., 49:2807, 1989, Pharmacokinetics . . . Malignancies.
Harris et al., Tibtech, 11:42, 1993, Therapeutic . . . Age.
Osband et al., Immunol. Today, 11:193, 1990, Problems . . . immunotherapy.
Hird et al., In Genes & Cancer, 1990 pp. 183-189.
Neuwelt et al., Cancer Res., 48:4725, 1988, Delivery . . . Disruption.
Y.S. Lee et al; Therapeutic Efficacy of Antiglioma Mesenchymal Extracellular Matrix .sup.131 I-Radiolabeled Murine Monoclonal Antibody in a Human Glioma Xenograft Model, Cancer Research 48, pp. 559-566 (1988).
Y. Lee et al; Treatment of Intracranial Human Glioma Xenografts with .sup.131 I-labeled Anti-Tenascin Monoclonal Antibody 81C6.sup.1, Cancer Research 48, pp. 2904-2910, May 15, 1988.
S. Clifford Shold, et al; Distribution and Dosimetry of I-123-Labeled Monoclonal Antibody 81C6 in Patients with Anaplastic Glioma, Investigative Radiology 28, pp. 488-496 (1993).
R. D. McComb, et al; Distribution of Type VI Collagen in Human Gilomas: Comparison with Fibronectin and Giloma-Mesenchymal Matrix Glycoprotein, Journal of Neuropathology and Experimental Neurology 46 pp. 623-633 (1987).
R.G. Blasberg, et al; Regional Localization of a Glioma-associated Antigen Defined by Monoclonal Antibody 81C6 in Vivo: Kinetics and Implications for Diagnosis and Therapy, Cancer Research 47, pp. 4432-4443 (Aug. 15, 1987).
M. A. Bourbon et al; Monoclonal Antibody Localization in Subcutaneous and Intracranial Human Glioma Xenografts: Paired-Label and Imaging Analysis, Anticancer Research 4, pp. 133-140 (1984).
D.E. Bullard, et al; Specific Imaging of Human Brain Tumor Xenografts Utilizing Radiolabelled Monoclonal Antibodies (MAbs), Nuklearmedizin 25, pp. 210-215 (1986).
C.J. Wikstrand, et al; Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model, Journal of Neuroimmunology 15, pp. 37-56 (1987).

Affiliated with

Also associated with

Rating

Method of treating brain tumors expressing tenascin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating brain tumors expressing tenascin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating brain tumors expressing tenascin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-703896